Jump Financial’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Jump Financial’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-21,500	Closed	-$817K	–	2164
2022 Q4	$817K	Buy	+21,500	New	+$740K	0.04%	569
2021 Q4	–	Sell	-22,500	Closed	-$2.26M	–	1819
2021 Q3	$2.26M	Buy	+22,500	New	+$2.64M	0.16%	121
2021 Q2	–	Sell	-6,500	Closed	-$648K	–	1471
2021 Q1	$648K	Buy	+6,500	New	+$758K	0.06%	340

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jump Financial's RETA Position: Q1 2023 in Review

Jump Financial sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 21,500 shares — an estimated $817K sold.

Jump Financial first reported a position in RETA in Q1 2021 and held it in 3 quarters. The position peaked at $2.26M in Q3 2021. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

Jump Financial reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Jump Financial sold 21,500 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $817K.
Jump Financial first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 3 quarters.
Jump Financial's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.26M in Q3 2021.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Jump Financial's 13F filing for Q1 2023, filed 3 May 2023.